Expert Interview
Examining the ESMO data on Nuvalent's NVL-655 (ALKove-1 study) and Roche's alectinib (P3 ALINA trial) for ALK+ NSCLC
Ticker(s): NUVL, RHHBYInstitution: University of Colorado Cancer Center
- Assistant Professor, Medicine-Medical Oncology at University of Colorado Anschutz Medical Campus
- Treats 588 patients with Non small cell lung cancer (NSCLC)
- Clinical and research interests include molecular diagnostics in lung cancer, managing acquired resistance to targeted therapies (such as ALK, EGFR, ROS1 tyrosine kinase inhibitors), and developing rational combinations of therapies based on evolutionary and molecular biology.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
